FREMONT, Calif., Feb. 14 /PRNewswire-FirstCall/ -- PDL BioPharma, Inc.
(PDL) (Nasdaq: PDLI) today announced that it will release its financial
results for the fourth quarter and year ended December 31, 2006 following
the close of the U.S. financial markets on Wednesday, February 21, 2007.
PDL will hold a conference call to discuss these financial results, its
commercial and clinical activities and its forward-looking information and
guidance at 4:30 p.m. Eastern time on February 21, 2007.
The live webcast of the conference call will be available through the
PDL website: http://www.pdl.com. Please connect to this website at least 15
minutes prior to the live webcast to allow time for any software download
that may be needed to hear the webcast. Financial and statistical
information to be discussed in the call will be available on the PDL
website immediately prior to the commencement of the call. A replay will be
available at http://www.pdl.com starting approximately one hour after completion
of the webcast.
An audio replay will also be available by telephone from approximately
6:30 p.m. Eastern time on February 21, 2007 through 6:30 p.m. Eastern time
on March 22, 2007. To access the replay, dial 800-642-1687 from inside the
U.S. and 706-645-9291 from outside the U.S.; enter conference ID number
8712465.
About PDL BioPharma
PDL BioPharma, Inc. is a biopharmaceutical company focused on
discovering, developing and commercializing innovative therapies for severe
or life-threatening illnesses. Commercially focused in the acute-care
hospital setting, PDL markets and sells its portfolio of leading products
in the United States and Canada. A pioneer of antibody humanization
technology, PDL promotes this technology through licensing agreements and
clinical development of its own diverse pipeline of investigational
compounds. PDL's research platform centers on the discovery and development
of antibodies to treat cancer and autoimmune diseases. For more
information, please visit http://www.pdl.com.
NOTE: PDL BioPharma and the PDL logo are considered trademarks of PDL
BioPharma, Inc.
SOURCE PDL BioPharma, Inc.
 back to top
Related links:
http://www.pdl.com/
CONTACT:
Ami Knoefler, Corporate and Investor
Relations, +1-510-284-8851, or ami.knoefler@pdl.com, or Jean
Suzuki, Corporate Relations, +1-510-574-1550, or
jean.suzuki@pdl.com, both of PDL BioPharma, Inc.
|
